



*M&A Update*

# Healthcare

December 2019

# Key Highlights

## *M&A in the United States*

The broad M&A market in the U.S. remains healthy even in light of economic and political uncertainties, while valuations continue to climb to record highs.

**Page 3**

## *M&A in the Healthcare Sector*

689 deals have been announced or completed in the sector so far in 2019, representing a 10% increase compared to the same time period last year.

**Page 4**

## *Notable Transactions*

The sector has witnessed a number of megadeals in 2019, including the \$11.1 billion acquisition of Array BioPharma by Pfizer and the \$16 billion acquisition of Coty, Inc. by JAB Cosmetics.

**Page 5**

## *Public Markets*

The healthcare sector continues to perform at high valuations relative to prior years, although it is lagging the S&P 500 overall.

**Page 6**



# M&A in the United States

## Deal Activity & Valuations


### Deal Activity

The broad U.S. M&A market in 2019 remains healthy despite economic uncertainty from trade tensions and recession risk. Though year-to-date activity has been lower than in the same time period in 2018 – total deal volume and value declined 28% and 23%, respectively – the current M&A environment is fundamentally strong due low interest rates, the bull market in stocks, high valuations and large capital reserves waiting to be deployed by strategic and financial acquirers.

<b>10,100</b> <b>M&amp;A Deals</b>	<b>\$1.4 Trillion</b> <b>Deal Value</b>
▼ 28% YoY decline	▼ 23% YoY decline

### Total M&A Deal Volume & Value in the United States

\$ in Billions; Year to date through November 30, 2019




### Valuations

Valuation levels continue to climb amid strong deal competition, cheap capital and high sellers' expectations. After reaching a lofty 10.8x in 2018, the median Enterprise Value (EV) to EBITDA multiple rose to double digits once again in 2019. The current benchmark of 10.9x EBITDA represents a 47% increase (equivalent to 3.5x EBITDA) vs. 2009 and marks the fifth consecutive year with valuation multiples north of 10.0x.

<b>10.9x</b>	<b>10.5x</b>
Current Median EV / EBITDA	5-Year Median EV / EBITDA

### Median Enterprise Value (EV) / EBITDA Valuation Multiple

Only includes transactions with disclosed financial terms; Year to date through November 30, 2019



Sources: S&P Capital IQ, Pitchbook, IMAA Institute, CCCA Research

Definitions: YoY = Year-over-year; Enterprise Value = Market Cap + Debt – Cash; EBITDA = Earnings Before Interest, Taxes, Depreciation & Amortization


# M&A in the Healthcare Sector

## Sector Snapshot


### Industries in the U.S. Healthcare Sector

- Long-Term & Behavioral Care
- Practice Management
- Provider Services
- Biotechnology & Life Sciences
- Drug & Medical Retail
- Medical Devices & Products
- Health, Fitness & Wellness
- Pharmaceutical Services


### Sector M&A Deal Volume



### M&A Deal Volume by Industry



### M&A Deal Volume by U.S. Region



Sources: S&P Capital IQ, Pitchbook, IMAA Institute, CCCA Research  
Definitions: YoY = Year-over-year

# M&A in the Healthcare Sector

## Notable Deals & Buyer Mix

### Notable Deals


Date	Company	Acquirer	Enterprise Value (EV) (\$ in MM)	Implied EV / Revenue	Implied EV / EBITDA
Oct 2019	Ra Pharmaceuticals (NasdaqGM:RARX)	UCB SA (EXNTRB:UCB)	\$2,170	-	-
Aug 2019	Cambrex Corp. (NYSE:CBM)	Permira Advisers	\$2,511	4.1x	15.7x
Jul 2019	Genomic Health	Exact Sciences Corporation	\$2,259	5.1x	-
Jun 2019	Array BioPharma	Pfizer, Inc. (NYSE:PFE)	\$11,076	-	-
May 2019	Acelity	3M Company (NYSE:MMM)	\$6,725	4.5x	15.2x
May 2019	Peloton Therapeutics	Merck & Co. (NYSE:MRK)	\$2,033	-	-
Feb 2019	Spark Therapeutics	Roche Holding AG (SWX:ROG)	\$4,513	-	-
Feb 2019	Coty, Inc. (NYSE:COTY)	JAB Cosmetics	\$16,514	1.9x	12.7x
Jan 2019	Loxo Oncology	Eli Lilly & Co. (NYSE:LLY)	\$7,391	-	-
Jan 2019	Celgene Corp. (NasdaqGS:CELG)	Bristol-Myers Squibb Co. (NYSE:BMJ)	92,778	5.5x	10.3x

Note: This table includes only a sample of relevant transactions in the context of M&A activity in the sector. It is not meant to be all-inclusive.

### Buyer Mix

#### Share of Acquisitions

% of Acquisitions by Strategic and Financial Acquirers



Sources: S&P Capital IQ, Pitchbook, IMAA Institute, CCCA Research

Definitions: Enterprise Value = Market Cap + Debt – Cash; EBITDA = Earnings Before Interest, Taxes, Depreciation & Amortization


# Public Companies in the Healthcare Sector

## Performance & Valuations

### Sector Performance

#### Return vs. S&P 500

Last 5 Years



### Valuations

#### Enterprise Value / LTM EBITDA

Median of Publicly Traded Companies



#### Enterprise Value / NTM EBITDA

Median of Publicly Traded Companies



Sources: S&P Capital IQ, Pitchbook, IMAA Institute, CCCA Research

Definitions: Enterprise Value = Market Cap + Debt - Cash; EBITDA = Earnings Before Interest, Taxes, Depreciation & Amortization; LTM = Last Twelve Months; NTM = Next Twelve Months

# CC Capital Advisors

## Firm Overview

### Who We Are

CC Capital Advisors is a boutique investment banking firm providing mergers and acquisitions, capital raising and strategic advisory services to middle market clients. Our experienced team of committed advisors combines long-standing transaction experience to provide independent and uncompromised services to achieve our clients' objectives.

### Who We Serve

We tailor our services to a broad base of clients, including entrepreneurs, family-owned businesses, private and public corporations, family offices, private equity and venture capital investors. Clients have repeatedly chosen us as trusted advisors and partners because of our quality advice, ability to execute transactions and client-first philosophy.

### What We Do

Mergers & Acquisitions	Capital Raising Advisory	Strategic Advisory
<ul style="list-style-type: none"><li>Sales of privately-held companies</li><li>Buy-side acquisitions</li><li>Minority buyouts</li><li>Corporate subsidiary divestitures</li><li>Private equity and venture capital portfolio divestitures</li></ul>	<ul style="list-style-type: none"><li>Senior secured and unsecured debt</li><li>Mezzanine capital</li><li>Growth equity capital</li><li>Recapitalizations</li><li>Private placements of institutional capital</li></ul>	<ul style="list-style-type: none"><li>Business valuations</li><li>Fairness opinions</li><li>Strategic options assessment</li><li>Ownership transition planning</li><li>Corporate reorganizations</li></ul>

### Why Clients Choose Us

<b>100+ Years</b>	Collective investment banking experience of our team	<b>\$7 Billion</b>	Completed transaction experience of our team
<b>Midwest Values</b>	Integrity, experience and commitment are our core values	<b>\$1 Billion</b>	Completed transaction value in the last five years
<b>Global Reach</b>	We represent clients across the world	<b>15 Deals</b>	Number of transactions closed since 2017

### Contact Our Team

**John Hense**  
Managing Director  
(816) 360-8646  
jhense@ccccapitaladvisors.com

**Bill Conway**  
Managing Director  
(816) 360-8697  
bconway@ccccapitaladvisors.com

**Terry Christenberry**  
Managing Director  
(816) 360-8698  
tchristenberry@ccccapitaladvisors.com

**Stephanie Siders, CFA**  
Vice President  
(816) 360-8695  
ssiders@ccccapitaladvisors.com

**Julian Buegers, CFA**  
Associate  
(816) 859-7513  
jbuegers@ccccapitaladvisors.com

**Chris Brito**  
Associate  
(816) 360-8694  
cbrito@ccccapitaladvisors.com

**Jack Rusgis, CPA**  
Analyst  
(816) 859-7462  
jrussgis@ccccapitaladvisors.com

**Jack Schanze**  
Analyst  
(816) 360-8600  
jschanze@ccccapitaladvisors.com

[www.ccccapitaladvisors.com](http://www.ccccapitaladvisors.com)



INTEGRITY. EXPERIENCE. COMMITMENT.

2001 Shawnee Mission Parkway, Suite 110  
Mission Woods, Kansas 66205  
816-360-8600

The information contained in this report was compiled by CC Capital Advisors from a variety of sources including news reports, S&P Capital IQ, Pitchbook, IMAA Institute, SEC filings, company statements, and information provided by M&A professionals. Many deals did not disclose pricing, and other private transactions may not have been publicly announced. Transactions are subject to change or termination prior to closing. While CC Capital Advisors makes a good faith effort to ensure the accuracy of this report, it is intended for general information purposes only. CC Capital Advisors is not responsible for any errors or omissions in this report.

Country Club Financial Services Inc., dba CC Capital Advisors, Member FINRA, SIPC